Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial. (linkinghub.elsevier.com)

Authors: Massonnaud CR … Hites M Journal: Clinical Microbiology and Infection Published: 2026-04-01 DOI: https://doi.org/10.1016/j.cmi.2025.12.014